We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL (VALIDATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04841434
Recruitment Status : Recruiting
First Posted : April 12, 2021
Last Update Posted : July 19, 2022
Information provided by (Responsible Party):
Stefan Schwartz, Charite University, Berlin, Germany

Brief Summary:

This phase I-II trial is intented to demonstrate tolerability (i.e. absence of severe non-hematological toxicity) and efficacy of intended intervention with repeated doses of Voraxaze, in addition to leucovorin (LV), in patients with renal impairment or renal failure during previous HD-MTX therapy.

Patients will receive up to 6 cycles of HD-MTX treatment with 14 days between cycles (a maximum delay of 28 days is permitted in order to allow time for a patient to recover from the previous cycle).

Condition or disease Intervention/treatment Phase
CNS Lymphoma Drug: Voraxaze Injectable Product Phase 1 Phase 2

Detailed Description:

MTX is used either alone or as part of a combined chemotherapy protocol either in standard or high doses in the treatment of a range of cancers and other diseases.

Dose escalation will be performed using three dose levels of MTX:

Level 1: 3.0 g/m2 Level 2: 3.5 g/m2 Level 3: 4.0 g/m2 Up to 6 patients will be treated at each dose level; each will receive a maximum of 6 cycles of treatment. The dose may be increased in Cycle 3 in individual patients to the next level, if renal function is adequate (GFR ≥ 40 mL/min, or in the case of decreased GFR, the decrease is <10% compared with the pre-treatment value), and absence of grade 3 or 4 non-hematological toxicities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Dose escalation will be performed using three dose levels of MTX.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With Central Nervous System Lymphoma and With Impaired Renal Function Being Treated With High-dose Methotrexate
Actual Study Start Date : June 1, 2021
Estimated Primary Completion Date : August 1, 2023
Estimated Study Completion Date : April 1, 2024

Arm Intervention/treatment
Experimental: Dose escalation
Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
Drug: Voraxaze Injectable Product
High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to <40 mL/min, or in the case of decreased GFR, the decrease is >50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing >100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
Other Name: High-dose Methotrexat Infusion

Primary Outcome Measures :
  1. Tolerability of Voraxaze [ Time Frame: 1 year ]
    absence of severe non-hematological toxicity

  2. Efficacy of Voraxaze [ Time Frame: 1 year ]
    immediate and sustained reduction in plasma MTX concentration

Secondary Outcome Measures :
  1. Dose Limiting Toxicities (DLTs) [ Time Frame: 1 year ]
    appearance of DLTs for each dose level of MTX

  2. Anti-glucarpidase antibodies [ Time Frame: at screening, prior to the MTX infusion at each treatment cycle and on day 28 of the last cycle ]
    presence of antibodies to glucarpidase

  3. MTX toxicities [ Time Frame: 1 year ]
    incidence and severity of hematological toxicities and stomatitis after each cycle of HD-MTX treatment and renal function before each cycle of HD-MTX treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary or secondary CNSL (PCNSL or SCNSL) confirmed by histology or cytology.
  • Renal insufficiency defined as a glomerular filtration rate (GFR, assessed by CKD-EPI or MDRD equation) of 40-80 mL/min or patients with a GFR >80mL/min who have experienced renal failure, defined as doubling of the serum creatinine compared to the baseline value during a previous HD-MTX treatment.
  • Age ≥ 18 years (male or female).
  • Life expectancy >3 months.
  • Adequate organ function (i.e., bone marrow, liver, lungs) allowing intensive chemotherapy with MTX.
  • Adequate clinical pathology values:
  • Absolute neutrophil count ≥1.0 x 109/L, hemoglobin ≥9mg/dL (transfusion allowed), platelets ≥100 x 109/L.
  • Total bilirubin ≤1.5x the upper limit of normal except for patients with known Gilbert syndrome.
  • Alanine amino-transferase (ALT) and aspartate amino-transferase (AST) ≤2x the upper limit of normal.
  • Alkaline phosphatase ≤2x the upper limit of normal.
  • Prothrombin time within the normal range for the institution.
  • Signed informed consent by the patient or legal representative prior to start of any study specific procedure.
  • Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study in such a manner that the risk of pregnancy is minimized. Acceptable contraceptives include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.

Exclusion Criteria:

  • Ongoing or expected need for therapy with drugs interfering with MTX-clearance (i.e., beta-lactam antibiotics, NSAIDs, probenicid, salicylates, sulphonamides) or other nephrotoxic drugs.
  • Prior brain radiotherapy within 28 days of first dose of the study drug.
  • Concurrent illness interfering with hydration (i.e., relevant congestive heart failure, SIADH syndrome).
  • Relevant third space (i.e., pleural effusion, ascites, extended edema) precluding HD-MTX treatment.
  • Obesity (body mass index >30 kg/m2).
  • Uncontrolled diabetes.
  • Active hepatitis.
  • HIV-infection.
  • Pregnant or lactating woman.
  • Participation in any other clinical trial either 1 month prior to or during this study.
  • Previous intolerance to any of the drugs used in this study (i.e., MTX, LV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04841434

Layout table for location contacts
Contact: Susen Burock, MD +49 (030) 450 564 648 susen.burock@charite.de

Layout table for location information
Charité Campus Benjamin Franklin (CBF) Recruiting
Berlin, Germany, 12200
Contact: Stefan Schwartz, MD    030 450 513382    stefan.schwartz@charite.de   
Sponsors and Collaborators
Charite University, Berlin, Germany
Layout table for additonal information
Responsible Party: Stefan Schwartz, PD Dr. med., Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT04841434    
Other Study ID Numbers: CNS-Lymphoma-Vorax-1
First Posted: April 12, 2021    Key Record Dates
Last Update Posted: July 19, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stefan Schwartz, Charite University, Berlin, Germany:
impaired renal function
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors